Business Model

DNDi’s primary objective is to deliver 6 - 8 new treatments by 2014 for VL, HAT, Chagas disease and malaria, and to establish a strong R&D portfolio that addresses patient treatment needs. The organisation will also use and strengthen existing capacity in disease-endemic countries via project implementation and will continue to raise awareness about the need to develop new drugs for neglected diseases and to advocate for increased public responsibility.

Business Plan 2007-2014

Objectives of DNDi's business plan:  

• A stronger focus on the kinetoplastid diseases;
• A stepwise, integrated model of drug R&D in which needs-driven projects are sourced at any stage of the pipeline;
• A virtual organisation which manages collaborative R&D projects;
• A needs-driven regulatory and access strategy;
• R&D networks that utilise and strengthen research capacities in disease-endemic countries;
• International advocacy to support DNDi’s R&D objectives and to foster an improved global framework for essential health R&D.

DNDi’s stepwise integrated model